Table 2.
Differences in plasma levels of oxylipins, endocannabinoids and their analogues between groups after 24 weeks of exercise intervention.
| MOD-EX vs. CON |
VIG-EX vs. CON |
MOD-EX vs. VIG-EX |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean difference | SE | 95% CI | P | Mean difference | SE | 95% CI | P | Mean difference | SE | 95% CI | P | |
| Oxylipins | ||||||||||||
| Omega-6-derived oxylipins | −1.486 | 0.527 | [−2.758; −0.214] | 0.016 | −0.832 | 0.526 | [−2.102; 0.438] | 0.345 | −0.653 | 0.548 | [−1.978; 0.671] | 0.705 |
| LA-derived oxylipins | −0.745 | 0.270 | [−1.398; −0.093] | 0.019 | −0.872 | 0.270 | [−1.525; −0.220] | 0.004 | 0.127 | 0.278 | [−0.545; 0.799] | 1.000 |
| DGLA-derived oxylipins | −0.128 | 0.082 | [−0.327; 0.071] | 0.365 | 0.004 | 0.082 | [−0.194; 0.203] | 1.000 | −0.133 | 0.085 | [−0.338; 0.073] | 0.361 |
| AA-derived oxylipins | −0.702 | 0.329 | [−1.497; 0.093] | 0.103 | −0.029 | 0.328 | [−0.820; 0.763] | 1.000 | −0.673 | 0.341 | [−1.497; 0.151] | 0.150 |
| AdrA-derived oxylipins | −0.173 | 0.057 | [−0.311; −0.036] | 0.008 | −0.116 | 0.057 | [−0.253; 0.021] | 0.129 | −0.057 | 0.059 | [−0.199; 0.084] | 0.988 |
| Omega-3-derived oxylipins | −0.708 | 1.067 | [−3.285; 1.869] | 1.000 | 0.150 | 1.052 | [−2.393; 2.693] | 1.000 | −0.858 | 1.094 | [−3.501; 1.785] | 1.000 |
| ALA-derived oxylipins | −0.943 | 0.757 | [−2.770; 0.885] | 0.643 | −0.416 | 0.757 | [−2.243; 1.412] | 1.000 | −0.527 | 0.779 | [−2.407; 1.353] | 1.000 |
| EPA-derived oxylipins | −0.097 | 0.174 | [−0.518; 0.324] | 1.000 | 0.220 | 0.174 | [−0.199; 0.639] | 0.620 | −0.317 | 0.180 | [−0.750; 0.117] | 0.237 |
| DHA-derived oxylipins | −0.254 | 0.318 | [−1.022; 0.515] | 1.000 | 0.452 | 0.315 | [−0.310; 1.214] | 0.460 | −0.706 | 0.327 | [−1.497; 0.085] | 0.097 |
| Ratio omega-6/3-derived oxylipins | −3.914 | 3.000 | [−11.229; 3.401] | 0.586 | 0.226 | 2.972 | [−7.022; 7.474] | 1.000 | −4.140 | 3.090 | [−11.675; 3.395] | 0.551 |
| Endocannabinoids and their analogues | ||||||||||||
| AEA | −0.033 | 0.025 | [−0.093; 0.027] | 0.561 | −0.021 | 0.025 | [−0.082; 0.039] | 1.000 | −0.012 | 0.026 | [−0.073; 0.050] | 1.000 |
| 2-AG | 0.008 | 0.078 | [−0.180; 0.195] | 1.000 | 0.136 | 0.077 | [−0.051; 0.324] | 0.239 | −0.129 | 0.081 | [−0.324; 0.066] | 0.335 |
| 2-LG | −0.034 | 0.113 | [−0.306; 0.238] | 1.000 | 0.055 | 0.113 | [−0.217; 0.327] | 1.000 | −0.089 | 0.116 | [−0.370; 0.192] | 1.000 |
| 2-OG | 0.012 | 0.113 | [−0.261; 0.286] | 1.000 | 0.119 | 0.114 | [−0.155; 0.394] | 0.887 | −0.107 | 0.118 | [−0.391; 0.177] | 1.000 |
| DHEA | −0.057 | 0.031 | [−0.132; 0.019] | 0.214 | −0.003 | 0.031 | [−0.079; 0.073] | 1.000 | −0.054 | 0.032 | [−0.132; 0.024] | 0.294 |
| DGLEA | −0.012 | 0.030 | [−0.085; 0.062] | 1.000 | −0.011 | 0.030 | [−0.084; 0.062] | 1.000 | −0.001 | 0.031 | [−0.077; 0.075] | 1.000 |
| LEA | −0.063 | 0.023 | [−0.117; −0.008] | 0.017 | −0.071 | 0.023 | [−0.126; −0.017] | 0.006 | 0.008 | 0.023 | [−0.048; 0.065] | 1.000 |
| α-LEA | −0.037 | 0.025 | [−0.098; 0.024] | 0.428 | −0.021 | 0.025 | [−0.082; 0.040] | 1.000 | −0.016 | 0.026 | [−0.079; 0.047] | 1.000 |
| PEA | −0.018 | 0.010 | [−0.042; 0.007] | 0.249 | −0.009 | 0.010 | [−0.033; 0.015] | 1.000 | −0.008 | 0.010 | [−0.033; 0.017] | 1.000 |
| PDEA | −0.032 | 0.022 | [−0.085; 0.020] | 0.407 | −0.014 | 0.022 | [−0.067; 0.038] | 1.000 | −0.018 | 0.022 | [−0.072; 0.036] | 1.000 |
| POEA | −0.061 | 0.044 | [−0.167; 0.045] | 0.493 | 0.008 | 0.044 | [−0.098; 0.113] | 1.000 | −0.069 | 0.045 | [−0.178; 0.040] | 0.391 |
| OEA | −0.054 | 0.020 | [−0.102; −0.006] | 0.021 | −0.023 | 0.020 | [−0.070; 0.025] | 0.765 | −0.031 | 0.020 | [−0.070; 0.025] | 0.374 |
| SEA | −0.021 | 0.011 | [−0.048; 0.007] | 0.211 | −0.002 | 0.011 | [−0.030; 0.026] | 1.000 | −0.019 | 0.012 | [−0.047; 0.010] | 0.338 |
Data is presented as estimated mean difference between groups, standard error (SE) and 95% confidence interval (CI) in each time point. P values obtained from post-hoc Bonferroni corrections from the linear mixed repeated measures analyses. Significant p values are highlighted in bold.
Abbreviations: 2-AG, 2-arachidonylglycerol; α-LEA, α-Linolenoyl ethanolamide; AA, arachidonic acid; AdrA, adrenic acid; AEA, anandamide; ALA, α-linolenic acid; CON, control group; DGLA, dihomo-γ-linolenic acid; DGLEA, dihomo-gamma-linolenoyl ethanolamide; DHA, Docosahexaenoic acid; DHEA, docosahexaenoyl ethanolamide; EPA, eicosapentaenoic acid; LA, linoleic acid; LEA, linoleoyl ethanolamide; MOD-EX, moderate-intensity exercise group; OEA, oleoyl ethanolamine; PDEA, pentadecanoyl ethanolamide; PEA, palmitoyl ethanolamide; POEA, palmitoleoyl ethanolamide; SEA, stearoyl Ethanolamide; VIG-EX, vigorous-intensity exercise group.